Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Tandem Diabetes Care, Inc. , a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version of the Tandem ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...

The global patient monitoring devices market size is expected to reach USD 118.21 billion by 2033, registering a CAGR of 10.21% from 2025 to 2033, according to a new report by Grand View Research, Inc ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

An international study co-led by University of Calgary researchers has found new insulin delivery technology helps control ...

Dexcom welcomed the advocates to a photoshoot in Los Angeles that included Grammy-nominated artist, actor, producer and ...